Investor Presentation

Date: October 29, 2026 To, To, Sr. General Manager Sr. General Manager Listing Department Listing Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Dalal Street Bandra Kurla Complex Mumbai – 400 001 Bandra (E), Mumbai – 400 051 BSE Scrip Code: 544319 NSE Symbol: SENORES Sub.: Investor Presentation for Q2 & H1FY27 Dear Sir/Ma’am, In terms of Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and our intimation dated October 22, 2026 and October 23, 2026 regarding the Earnings Conference Call, we enclose herewith the Investor Presentation for Q2 & H1FY27. The aforesaid information will be hosted on the Company's website at www.senorespharma.com. You are requested to take the same on record. Thanking you. For Senores Pharmaceuticals Limited Shilpa Sharma Company Secretary & Compliance Officer Membership Number: A34516 Enclosure: As above Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263 Investor Presentation October 2026 Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Senores Pharmaceuticals Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offeringdocument containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of,or any omissionfrom,this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible forsuch third-party statements and projections. All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness. Financial & Operational Highlights Q2 & H1FY27 Private & Confidential Key Highlights – Q2 & H1FY27 Consistently strong delivery REVENUE GROWTH EBITDA GROWTH EBITDA MARGIN EXPANSION CASH FROM OPERATIONS 25% 30% 38.4% 58.2% ~290 ~530 ₹38 ₹31 bps bps Cr Cr Q2 FY27 H1 FY27 Q2 FY27 H1 FY27 Q2 FY27 H1 FY27 H1 FY27 H1 FY26 Strong EBITDA growth even while investing for the future Q2 and H1 FY27 EBITDA grew 38.3% and 58.2% despite investments in Apnar (last 6 months) and ongoing investments in Zoraya & Amerisyn (revenues to ramp up over the next 12 months). Excluding these investments, which will reap future benefits, EBITDA growth would have been much higher. What drives the H2 outlook Senores group companies INDIA Robust approved & pipeline products Strong growth visibility – H2 expected to be considerably better than H1 owing to anticipated launches R&D intensity at 11% of revenue R&D expenses stood at 11% of revenue in H1 FY27 Forward integration Zoraya and Amerisyn to begin contributing to revenues from H2 FY27 AmerisynLLC (A subsidiary of Senores Pharmaceuticals Inc.) Regulated Market Owned Product Portfolio & Visibility Owned ANDAs Corresponding ANDA Products* Key Highlights Q2FY26 Q2FY27 Q2FY26 Q2FY27 64 207 Approved ANDAs 34 81 • Commercialized 3 new strengths in Q2FY27 under existing ANDAs, including 2 being sold in the US for the first timeby any company. Commercialized 23 54 • Received approvalfor 1 ANDA 16 32 and 3 sANDA’sin Q2FY27. ANDAs • 41 ANDAs with Corresponding 153 ANDA Products* to be launched • Expecting 13 ANDAs with 41 ANDAs Yet To 41 153 strengths to be commercialized in 18 49 government channel in H2FY27. Launch • Robust Pipeline of 41 molecules with 130 unique strengths under development. Molecules Under 41 130 35 70 Development *ANDA Products represents individual strengths associated with an ANDA 5 CDMO / CMO & Emerging Market Opportunity Regulated Markets ANDAs Corresponding ANDA Products* Huge Opportunity Q2FY26 Q2FY27 Q2FY26 Q2FY27 CDMO/CMO business focused on specialty, government supplies CDMO/ CMO and controlled substances. 19 46 Commercialized 16 32 Uniquely positioned in USA & Products India to provide end-to-end solutions from development to commercialization. CDMO / CMO 34 108 Commercialized3 more partner 13 45 ANDAs and 12 Strengths in Pipeline Products Q2FY27 Significantly enhances efficiency, scale & utilization, leading to better operating leverage. Approved Products Products under Registration 558 942 944 513 858 478 824 Emerging Markets 450 Significant expansion of the Approved and Pipeline product Portfolio portfolio across 40+ countries creating a strong runway for future growth. Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 *ANDA Products represents individual strengths associated with an ANDA Consolidated Financial Highlights – Q2 & H1FY27 Revenue (₹ Crs) EBITDA (₹ Crs) PAT (₹ Crs) +30% +58% +31% 372.5 111.4 67.0 286.5 22% 51.3 25% 38% 70.4 36.6 192.3 57.7 30.1 153.9 41.7 Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 Q2 FY26 Q2 FY27 H1 FY26 H1FY27 Gross Margin (%) EBITDA Margin (% ) PAT Margin (%) +250 bps +580 bps +290 bps +530 bps +10 bps -60 bps 62.9 65.4 64.5 30.0% 29.9% 19.6% 19.0% 58.7 27.1% 17.9% 18.0% 24.6% Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 Q1 FY26 Q1 FY27 H1 FY26 H1 FY27 Segmental Financial Highlights – Q2 & H1FY27 Segment Revenue (₹ Crs) Q2FY27 Q2FY26 Y-o-Y H1FY27 H1FY26 Y-o-Y Regulated Markets 136.7 106.9 27.9% 264.5 196.9 34.3% Emerging Markets 38.4 31.7 21.2% 76.0 60.7 25.3% Branded Generics 9.5 11.9 -20.5% 17.5 20.2 -13.4% Others 7.8 3.4 126.2% 14.6 8.7 67.2% Total Revenue 192.3 153.9 24.9% 372.5 286.5 30.0% • Regulated Markets - EBIDTA Margin for H1 FY27 stood at ~42%. Regulated Markets contributed to 71% of total revenue in H1FY27 • Emerging Markets - EBIDTA Margin for H1 FY27 stood at ~9%. Emerging Markets contributed 20% of total revenue in H1FY27 Consolidated Profit & Loss [Showing first 8,000 characters — download PDF for full document]